{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0056","pValueComment":"A priori threshold for statistical significance=0.05.","statisticalComment":"Cochran-Mantel-Haenszel test stratified by Hasford Score.","statisticalMethod":"Cochran-Mantel-Haenszel","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"204"},{"groupId":"OG001","value":"177"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"259"},{"groupId":"OG001","value":"260"}],"units":"Participants"}],"description":"Cytogenetic response (CyR) is based on the prevalence of Philadelphia positive (Ph+) cells in metaphase from bone marrow (BM) sample. (Ideally, 25 metaphases but at least 20 metaphases from a BM sample were evaluated). Complete Cytogenetic Response (CCyR)=0% Ph+ cells in metaphase in BM. A cCCyR=those in which all measurements up to at least 28 days after the initial response show an equivalent or better CCyR.","groups":[{"description":"Tablets, oral, dasatinib 100 mg once daily (QD)","id":"OG000","title":"Dasatinib"},{"description":"Tablets, oral, imatinib 400 mg once daily (QD)","id":"OG001","title":"Imatinib"}],"paramType":"NUMBER","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"Pretreatment, every 3 months up to 12 months","title":"Number of Participants With Best Confirmed Complete Cytogenetic Response (cCCyR) Within 12 Months","type":"PRIMARY","unitOfMeasure":"Participants"}